Brookstone Capital Management Sells 71 Shares of Zoetis Inc. (NYSE:ZTS)

Brookstone Capital Management trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,767 shares of the company’s stock after selling 71 shares during the period. Brookstone Capital Management’s holdings in Zoetis were worth $614,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Darwin Wealth Management LLC bought a new position in Zoetis during the third quarter worth about $31,000. First Personal Financial Services bought a new position in Zoetis during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC increased its stake in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP raised its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ZTS shares. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $211.89.

Zoetis Trading Down 2.0 %

NYSE ZTS opened at $166.01 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock’s 50 day moving average price is $171.15 and its two-hundred day moving average price is $179.99. The stock has a market capitalization of $74.90 billion, a price-to-earnings ratio of 31.20, a PEG ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the company earned $1.36 earnings per share. The firm’s revenue was up 11.6% compared to the same quarter last year. As a group, analysts anticipate that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.20%. Zoetis’s payout ratio is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.